300+ investors in your industry, stage, and region Get
Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Platforms
Enterprise Software
Local
Travel
InsurTech
Retail
Oil and Gas
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Medical Device
Education
Wellness
Sports
Automotive
Biotechnology
eSports
Legal
Renewable Energy
Software
Crowdfunding
Recruiting
Web3
Medical
Venture Capital
Theatre
Climate
LGBT
Cannabis
Social
Celebrity
Life Science
Food and Beverage
Infrastructure
Publishing
Mobile Apps
Wine and Spirits
Beauty
Music
Art
Fashion
Real Estate
Sporting Goods
Manufacturing
Social Media
Financial Services
FinTech
Franchise
Non Profit
Finance
Internet
Mobile Advertising
Digital Media
Android
Proptech
Enterprise
Impact
Sustainability
Hardware
Community
Biotech
Transportation
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Singapore
Brazil
LATAM
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Hong Kong
Oceania
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Poland
Romania
Oman
Puerto Rico
Cameroon
Guernsey
China
Colombia
Armenia
Czech Republic
Costa Rica
Kenya
Marshall Islands
Kuwait
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Botswana
Seychelles
Paraguay
Canada
South Africa
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Ireland
Senegal
Tanzania
India
Germany
United States
Middle East
Indonesia
Dominican Republic
Bermuda
Asia
Albania
Spain
Europe
Argentina
Qatar
Angola
Cyprus
Barbados
Belgium
Jordan
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Bolivia
Bangladesh
Belize
Algeria
Italy
Belarus
Finland
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database

MINTS

VC Fund

Ann Arbor, United States

MINTS is a VC fund in Ann Arbor focused on Health Care and Medical. MINTS initiative is a $25m venture fund for the University of Michigan to leverage commercialization efforts by the Office of Technology Transfer (OTT) for investment purposes while demonstrating support for U-M start-ups. The program will be managed by the University’s Investment office, with the support of OTT and the General Counsel’s Office, aspart of the University’s long-term portfolio of investments.

Total investments:
11
Last investment:
Lead investor:
0%

Last updated:

Industries MINTS invests in

Health CareMedicalSoftwareTherapeuticsBiotechnology

Stages MINTS invests in

Series ASeedSeries BSeries CFunding Round

Countries MINTS invests in

United StatesBelgium

Investment Focus

Industry

  • Health Care 5 (45%)
  • Medical 3 (27%)
  • Software 2 (18%)
  • Therapeutics 2 (18%)
  • Biotechnology 2 (18%)
See all 15 industries →

Stage

  • Series A 3 (27%)
  • Seed 2 (18%)
  • Series B 2 (18%)
  • Series C 1 (9%)
  • Funding Round 1 (9%)
See all 6 stages →

Country

  • United States 5 (45%)
  • Belgium 1 (9%)

Investments

CompanyDescriptionRoundLinks
Confo Therapeutics Confo Therapeutics
Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO body-stabilized active state conformations ofthese receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention. $65.2M / Series B / Jul 26, 2024
ONL Therapeutics ONL Therapeutics
ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. The current market for retinal drugs is greater than $7 billion and rapidly growing. Existing therapies have significant limitations and none address the initial neural component of vision loss - the death of the photoreceptorcell. $15M / Series C / Mar 08, 2023
CubeWorks CubeWorks
CubeWorks’ mission is to accelerate the future of IoT and build a world connected by ubiquitous sensor technology through millimeter-scale smart sensing solutions. In 2013, following a decade of research on ultra-low-power circuitry at the University of Michigan, CubeWorks was founded to advance the next generation of IoT sensors. Today, with thedevelopment of the CubiSens™ Platform, CubeWorks brings to market a portfolio of ultra-small wireless smart sensors. These sensors offer limitless potential across a broad range of applications and provide access to mission-critical information exactly when and where it is needed. $2.4M / Seed / Jun 01, 2022
FlexDex FlexDex
FlexDex is a minimally invasive surgery medical device technology that provides high dexterity. Its platform technology translates the surgeon’s hand, wrist, and arm movements from outside the patient into corresponding movements of an end-effector inside the patient’s body.The company was founded in 2010 and is headquartered in Brighton,Michigan. $13M / Venture - Series Unknown / Aug 24, 2021
ONL Therapeutics ONL Therapeutics
ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. The current market for retinal drugs is greater than $7 billion and rapidly growing. Existing therapies have significant limitations and none address the initial neural component of vision loss - the death of the photoreceptorcell. $46.9M / Series B / Dec 22, 2020
Ripple Science Ripple Science
Ripple Science delivers web-based software and an active registry that facilitates the recruitment and management of research participants for clinical and translational studies. By adapting sales and marketing automation tools to the process of participant recruitment, Ripple empowers its customers to recruit more participants faster.Thecompany's flagship product, Ripple SaaS, is currently being used by research investigators at more than 75 academic and research centers around the world, including Johns Hopkins University, Pennsylvania State University, University of California Los Angeles, the Brain Research Foundation Canada, University of East Anglia, Cognito Therapeutics, and the University of Michigan. $2.5M / Jan 07, 2020
Ripple Science Ripple Science
Ripple Science delivers web-based software and an active registry that facilitates the recruitment and management of research participants for clinical and translational studies. By adapting sales and marketing automation tools to the process of participant recruitment, Ripple empowers its customers to recruit more participants faster.Thecompany's flagship product, Ripple SaaS, is currently being used by research investigators at more than 75 academic and research centers around the world, including Johns Hopkins University, Pennsylvania State University, University of California Los Angeles, the Brain Research Foundation Canada, University of East Anglia, Cognito Therapeutics, and the University of Michigan. $2.5M / Seed / Jan 07, 2020
Confo Therapeutics Confo Therapeutics
Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO body-stabilized active state conformations ofthese receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention. $33.6M / Series A / May 07, 2019
Fifth Eye Fifth Eye
Fifth Eye develops a medical device software that provides a view of a patient’s evolving hemodynamic trajectory. It enables proactive patient care to improve outcomes, avoid adverse events, shorten lengths of stay, and reduce costs. $11.5M / Series A / Apr 01, 2019
Ripple Science Ripple Science
Ripple Science delivers web-based software and an active registry that facilitates the recruitment and management of research participants for clinical and translational studies. By adapting sales and marketing automation tools to the process of participant recruitment, Ripple empowers its customers to recruit more participants faster.Thecompany's flagship product, Ripple SaaS, is currently being used by research investigators at more than 75 academic and research centers around the world, including Johns Hopkins University, Pennsylvania State University, University of California Los Angeles, the Brain Research Foundation Canada, University of East Anglia, Cognito Therapeutics, and the University of Michigan. $1.8M / Seed / Jun 15, 2018
See all 11 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Platforms
Enterprise Software
Local
Travel
InsurTech
Retail
Oil and Gas
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Medical Device
Education
Wellness
Sports
Automotive
Biotechnology
eSports
Legal
Renewable Energy
Software
Crowdfunding
Recruiting
Web3
Medical
Venture Capital
Theatre
Climate
LGBT
Cannabis
Social
Celebrity
Life Science
Food and Beverage
Infrastructure
Publishing
Mobile Apps
Wine and Spirits
Beauty
Music
Art
Fashion
Real Estate
Sporting Goods
Manufacturing
Social Media
Financial Services
FinTech
Franchise
Non Profit
Finance
Internet
Mobile Advertising
Digital Media
Android
Proptech
Enterprise
Impact
Sustainability
Hardware
Community
Biotech
Transportation
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Singapore
Brazil
LATAM
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Hong Kong
Oceania
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Poland
Romania
Oman
Puerto Rico
Cameroon
Guernsey
China
Colombia
Armenia
Czech Republic
Costa Rica
Kenya
Marshall Islands
Kuwait
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Botswana
Seychelles
Paraguay
Canada
South Africa
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Ireland
Senegal
Tanzania
India
Germany
United States
Middle East
Indonesia
Dominican Republic
Bermuda
Asia
Albania
Spain
Europe
Argentina
Qatar
Angola
Cyprus
Barbados
Belgium
Jordan
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Bolivia
Bangladesh
Belize
Algeria
Italy
Belarus
Finland
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does MINTS invest in?

MINTS invests primarily in Health Care, Medical and Software startups, most often at Series A and Seed stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

When did MINTS last invest?

The most recent investment recorded for MINTS closed in Jul 2024. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
MINTS Find emails